


Curriculum Vitae

Name	Teresa MACARULLA	
Current Position & Affiliation	Head of Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron	
Country	Spain	

Educational Background

- medical degree from the Universitat Autònoma de Barcelona in Barcelona, Spain.
- specialist training in medical oncology and has had appointments in Barcelona.

Professional Experience

- Head of Gastrointestinal and Endocrine Tumor Unit at Vall d'Hebron University Hospital
- Principal Investigator, at VHIO
- Associate teacher of the Universitat Autònoma de Barcelona, assigned to the Department of Medicine. Barcelona, Spain.
- Attending Physician, Gastrointestinal Tumors Service, Medical Oncology Service, University Hospital of Vall d'Hebron. Barcelona, Spain
- Program Clínico de Intercambio en el Memorial Sloan Kettering Cancer Center. New York, Estados Unidos.
- Residency, Department of Medical Oncology, University Hospital Sant Pau, Universitat Autònoma de Barcelona. Barcelona, Spain. Number 832 for examination: MIR 2000.

Professional Organizations

- Vall d'Hebron Institute of Oncology (V.H.I.O.)
- Vall d' Hebron University Hospital

Main Scientific Publications

Feliu J, Jorge Fernández M, Macarulla T, Massuti B, Albero A, González González JF, Quintero-Aldana G, Delgado-Mingorance JI, Fernández Montes A, García Piernavieja C, Valladares-Ayerbes M, López Muñoz AM, Mondéjar Solís R, Vicente P, Casado Gonzalez E, González Cebrián I, López-Vivanco G. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. *Cancer Chemother Pharmacol.* 2021 Jan 15. doi: 10.1007/s00280-020-04214-w.

Chen LT, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.

Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T. Practical considerations in the use of regorafenib in metastatic colorectal cancer. *Ther Adv Med Oncol.* 2020 Oct 31;12:1758835920956862. doi: 10.1177/1758835920956862

Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA 3rd. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. *Br J Cancer.* 2020 Sep 11. doi: 10.1038/s41416-020-01041-x

Verdaguer H, Acosta D, Macarulla T. A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer *Future Oncol.* 2020 Aug 17. doi: 10.2217/fon-2020-0334.

Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
J Clin Oncol. 2020 Jul 24;JCO2000590. doi: 10.1200/JCO.20.00590

Dopazo C, Lladó L, Fondevila C, Macarulla T, Navalpotro B, Ramos E, Fabregat J, Laquente B, Navasa M, Castells L, Bilbao I, C García Valdecasas J, Charco R. Applicability and results of liver transplant combined with neoadjuvant chemoradiotherapy in the treatment of unresectable hilar cholangiocarcinoma
Cir Esp. 2020 Jul 15;S0009-739X(20)30216-5. doi: 10.1016/j.ciresp.2020.06.009

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol. 2020 May 13. pii: S1470-2045(20)30157-1. doi: 10.1016/S1470-2045(20)30157-1

Golan, Talia; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; Hall, Michael J; Park, Joon-Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do-Youn; Reinacher-Schick, Anke; Tortora, Giampaolo; Algul, Hana; O'Reilly, Eileen M; McGuinness, David; Cui, Karen Y; Schlienger, Katia; Locker, Gershon Y; Kindler, Hedy L Maintenance Olaparib for Germline *BRCA*-Mutated Metastatic Pancreatic Cancer.
The New England journal of medicine, 2019-Jun-02

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. "Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease."
Lancet Oncol. 2018 Mar;19(3):e151-e160

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartzmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT. "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial." *Lancet*. 2016 Feb 6; 387(10018):545-57.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."

Lancet Oncol. 2010 Aug; 11(8):753-62
